#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hyperadrenocorticism Retinal dystrophy Arterial tortuosity syndrome Fms-like tyrosine kinase 3 positive Immune-mediated renal disorder Erythema multiforme Pleural mesothelioma malignant Indolent systemic mastocytosis Cardiac failure acute Pancreatic neuroendocrine tumour Liposarcoma Usher's syndrome Immune-mediated myositis Myxofibrosarcoma Angiosarcoma metastatic More trials…

    Learn about Rare Diseases

    Ehlers-Danlos syndrome – Treatment Haemophilia B with anti factor IX – Treatment Familial haemophagocytic lymphohistiocytosis – Trials in Disease Piriformis syndrome – Diagnostics Netherton’s syndrome Phenylketonuria Atypical haemolytic uraemic syndrome – Diagnostics Retinoblastoma – Diagnostics Sarcoma – Trials in Disease Osteosarcoma metastatic More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Warfarin Sodium Belatacept Teprenone Clopidogrel Hydrogen Sulfate Rct2100 Etrasimod Arginine Lovotibeglogene Autotemcel Antiemetics And Antinauseants Jnj-64042056 Tavapadon Buprenorphine Levobupivacaine Hydrochloride LTX-002 SODIUM CICLOPIROX Tulmimetostat Lu Ag09222 NORELGESTROMIN Reboxetine Inupadenant Deoxyribonucleic Acid More therapies…

    Learn about Your Condition

    Haematological malignancy Hyperadrenocorticism Fabry's disease Thyroid mass Mucopolysaccharidosis II Skin angiosarcoma Small intestine adenocarcinoma Neurodermatitis Bile duct adenocarcinoma Malignant melanoma stage IV Myelodysplastic syndrome Varices oesophageal Leiomyosarcoma recurrent Haemorrhage Erosive oesophagitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Osteosarcoma metastatic

  • Study on the Effectiveness of Denosumab with Chemotherapy (Cisplatin, Methotrexate, Doxorubicin) for Patients with Metastatic Osteosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Osteosarcoma metastatic
    Investigated Drugs:
    • Denosumab
    • Cisplatin
    • Doxorubicin Hydrochloride
    Italy

  • Study on Mifamurtide with Chemotherapy for Patients with High-Risk Osteosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Osteosarcoma metastatic
    • Osteosarcoma
    Investigated Drugs:
    • Mifamurtide
    • Cisplatin
    • Doxorubicin Hydrochloride
    France

  • Study on the Safety and Tumor-Fighting Effects of OMO-103 for Patients with Advanced Osteosarcoma

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Osteosarcoma metastatic
    Investigated Drugs:
    • Omo-103
    Spain

  • Study on the Effectiveness and Safety of Regorafenib for Patients with Resistant Primary Bone Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Osteosarcoma recurrent
    • Ewing’s sarcoma recurrent
    • Osteosarcoma metastatic
    Investigated Drugs:
    • Regorafenib
    Poland

  • Study on the Effectiveness and Safety of Regorafenib for Patients with Metastatic Bone Sarcomas

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chondrosarcoma metastatic
    • Chordoma
    • Osteosarcoma metastatic
    Investigated Drugs:
    • Regorafenib
    France

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!